Intensity Therapeutics (INTS) Other Working Capital Changes (2022 - 2023)
Intensity Therapeutics' (INTS) quarterly Other Working Capital Changes came in at $823.0 in Q3 2023, up 101.79% YoY from $407.84 in Q3 2022, and up 101.79% on a QoQ basis from -$45889.0 in Q3 2022.
Intensity Therapeutics (INTS) Other Working Capital Changes (2022 - 2023) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Other Working Capital Changes data on file, last reported at -$127000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 149.02% year-over-year to -$127000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63000.0 (down 125.2% YoY) and the FY2025 annual result came in at $13000.0, up 104.32% from the prior year.
- Other Working Capital Changes rose to $823.0 in Q3 2023, from -$45889.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $823.0 in Q3 2023 to a low of -$45889.0 in Q3 2022.
- A 5-year average of $109008.1 and a median of $31000.0 in 2023 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes jumped 2781.3% — and 2024, when it plunged 5920.0%.
- Tracing INTS's Other Working Capital Changes over 5 years: stood at -$50647.0 in 2022, then jumped by 2781.3% to $1.4 million in 2023, then slumped by 115.1% to -$205000.0 in 2024, then sank by 61.46% to -$331000.0 in 2025, then soared by 61.63% to -$127000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$127000.0 (Q1 2026), -$331000.0 (Q4 2025), and $297000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 823.00 |
| Sep 30, 2023 | 823.00 |
| Sep 30, 2023 | 823.00 |
| Sep 30, 2022 | -45,889.00 |
| Sep 30, 2022 | -45,889.00 |
| Sep 30, 2022 | -45,889.00 |